Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW590735 in Dyslipidemia
NCT00169559Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2003
- Primary completion
- Apr 2005
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of GW590735 in dyslipidemia (3 arms), sponsored by GSK. Primary endpoint: Change from baseline in fasting plasma HDLc concentration at 8 weeks. Started Nov 2003; status: completed.
02
Drugs
GW590735
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT00169559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00169559.